Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases
-
EU unveils strategy to boost Arctic presence
-
Vote count begins in Alberta secession referedum, testing Canada unity
-
How recent controversies have rocked the US death penalty debate
-
Ukraine claims US missile holdup as Trump floats summit without Zelensky
-
Adams facing long injury layoff as Rams' problems deepen
-
Detained Suu Kyi receives UK royal package: Myanmar govt
-
US judge orders Saudi engineer held in OpenAI case
-
Japan successfully launches probe in historic Mars moon mission
-
Maddison sparkles as Spurs end Premier League winless run
-
US to auction deep sea mining leases off American Samoa
-
Maddison sparkles on Spurs return as win drought ends
-
Australian lawmaker hurt in car attack underwent surgery overnight: PM
-
Trump says ready to meet with Putin and Xi in China
-
Japan launches rocket for potential world first Mars moon mission
-
The young lawmaker making Brazil's Lula 'king of the selfie'
-
Ethiopia PM warns Eritrea of 'severe consequences' if supports enemies
-
Christiane Amanpour to leave CNN after 43 years
-
Boland grabs opportunity for Australia as South Africa struggle in second Test
-
Ronaldo handed 30-day suspension after walking out on Portugal
-
Ronaldo handed 30-day suspension: Portuguese federation
-
Netanyahu basks in Trump endorsement week before election
-
France announces curfews as government grapples with unrest
-
Saudi airport closure disrupts life in kingdom's capital
-
Boland sets pace as South Africa struggle
-
Ramaphosa tells South Africa to prepare for loss of US-Africa trade deal
-
Ukraine on back foot as Kremlin moots US, China meeting
-
France presses resale platforms to remove 'stolen' goods after unrest
-
'Stay home!': Tourists find themselves in a France convulsed by protests
-
Yamal v PSG: Ballon d'Or backdrop to Champions League showdown
-
Kenyan cult leader guilty on all charges over 191 starvation deaths
-
Araujo says too soon to talk about permanent Liverpool move
-
Eagles star Hurts to miss rest of NFL season: reports
-
US wants to be 'strong partner' for central Asia: Rubio
-
Oil-rich Alberta votes on Canada breakup
-
'Special' to face friend Perez in Champions League, says Liverpool's Iraola
-
Israel announces arrests after West Bank settler attacks on Westerners
-
Monitor says Indonesia fires have burned nearly two million hectares
-
Guehi insists players have 'trust and belief' in Man City after charges
-
French PM says could declare state of emergency over unrest 'if needed'
-
UN climate panel head wants swift end to deadlock over key scientific report
-
Albanian PM warns of 'red line' after days of unrest
-
PM calls for curfews in France as govt grapples with unrest
-
Putin, Xi and Trump could meet at APEC summit: Kremlin
-
Man City's Semenyo out for up to eight weeks
-
Microsoft exits data centre deal in blow to UK AI ambitions
-
Australian lawmaker critically hurt in 'violent' vehicle attack
-
European stocks retreat as France violence spreads
-
England women's coach Wiegman signs two-year contract extension
-
North Korea warns 'grave situation' prevailing along border
-
Louvre blocked as France grapples with unrest
Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases
Click here to register for event
To access the replay of the June 10, 2026 presentation by Lisa Conte, Jaguar's founder, president & CEO, at the Emerging Growth Conference, click here
Reminder: Two crofelemer presentations in pediatric intestinal failure patients with microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) to be conducted at June 24-27, 2026 Annual European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) Meeting
SAN FRANCISCO, CA / ACCESS Newswire / June 12, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Wednesday, June 24, 2026 at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com.
Participation Instructions for Jaguar's Presentation at the Life Sciences Virtual Investor Forum
When: Wednesday, June 24, 2026 at 1:00 PM Eastern
Registration link for conference: Click Here
Replay: A replay of the webcast will be available following the conclusion of the conference.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. ("Jaguar") develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal ("GI") disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will present at the June 2026 conference listed above, and the expectation that two crofelemer-related presentations in pediatric intestinal failure patients with MVID and SBS-IF will be made at the 58th ESPGHAN Annual Meeting in June 2026. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
[email protected]
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire
G.Stevens--AMWN
